HSCT FOR AUTOIMMUNE DISEASES

Maria Carolina Oliveira, Milton Artur Ruiz, Daniela Moraes, Juliana Elias Dias, Lilian Piron-Ruiz, Andreza Feitosa Ribeiro, Morgani Rodrigues, Nelson Hamerschlag

1Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
2Center for Cell-based Therapy, Regional Blood Center, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil - 3 Bone Marrow Transplantation and Cell Therapy Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil - 4Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil

Key words: autoimmune diseases, hematopoietic stem cell transplantation, multiple sclerosis, systemic sclerosis, Crohn’s disease

Correspondence to: mcarolor@usp.br

Autologous hematopoietic stem cell transplantation (AH SCT) has been used worldwide as treatment for autoimmune disease patients, and although different centers have slightly different approaches, the main strategy remains similar1. Briefly, the procedure consists of a first phase, when autologous hematopoietic stem cells are harvested (mobilized) and cryopreserved, and a second phase, including conditioning regimen and infusion of stem cells. The aim of AH SCT is to promote immune depletion, eliminate autoreactive lymphocytes and reprogram the immune system, restoring long-lasting immune tolerance. As result, patients maintain long-term clinical remission in absence of further immunosuppression.

Three of the most important and current indications for AH SCT are multiple sclerosis (MS), systemic sclerosis (ES) and Crohn’s disease (CD)11. The American Society for Cellular Transplantation and Therapy (ASTCT), the European Society for Blood and Marrow Transplantation (EBMT) and the Brazilian Society of Bone Marrow Transplantation (SBTMO) currently consider AH SCT as part of the already established therapeutic strategies for these three autoimmune disorders, apart from the research setting.

### MULTIPLE SCLEROSIS

In addition to numerous studies published since 1993, two randomized clinical trials are available in the literature. In the ASTIMS study, AH SCT was compared to mitoxantrone; 9 of 21 MS patients were randomized to AH SCT, conditioned with BEAM and rabbit antithymocyte globulin (ATG)2. In this study, patients with an average disease duration of 10 years were included, most of them already in the secondarily progressive phase of the disease. Over 4 years, the average number of new T2-weighted magnetic resonance imaging (MRI) lesions was 2.5 in the AH SCT group versus 8 in the mitoxantrone group (p=0.00016). None of the transplanted patients presented new MS lesions at MRI with gadolinium. The progression of the Expanded Disability Status Score (EDSS) was similar in both groups, worsening in 57% of the patients in the AH SCT group, versus 48% in the mitoxantrone group (p=0.50). More recently, a multicenter study compared AH SCT with the best available treatment chosen by the neurologists at each center. One hundred and ten patients with highly inflammatory MS (relapsing-remitting subset and inflammation on MRI) were randomized. The AH SCT group was conditioned with 200 mg/kg cyclophosphamide plus rabbit ATG. In the first year of follow-up, the EDSS decreased (neurological improvement) in the transplanted patients, while increased in the non-transplanted patients (p <0.01). In 5-year follow-up, the EDSS worsened in 3/52 (5.8%) patients in the AH SCT group, against 34/51 (66.7%) in the non-transplanted group, and there were relapses in 15.4% of patients in the AH SCT group versus 85.2% in the non-transplanted group. There were no deaths or grade 4 toxicities related to transplant.

In 2019, the American Society for Transplantation and Cell Therapy (ASTCT) published a comprehensive review of the literature and recommended AH-
SCT as "standard of care, available clinical evidence" for relapsing-remitting, treatment-refractory MS[8].

Patients to be considered for transplantation should have inflammatory phenotypes of MS, which include patients with the relapsing-remitting form having presented well-defined relapses in the last 12 months, or patients with the secondary progressive form showing inflammatory lesions (gadolinium enhancement or new T2 lesions) on MRI images in the last 12 months.

**SYSTEMIC SCLEROSIS**

Case reports and phase I/II studies have been published since 1996, demonstrating safety and efficacy of autologous transplantation for SSc. In the last decade, three randomized studies have shown that AHSCST is superior to conventional treatment in patients with SSc, promoting greater overall survival, progression-free survival and quality of life.

The first study included 19 SSc patients, who were randomized either to non-myeloablative AHSCST with 200 mg/kg cyclophosphamide plus rabbit ATG or to conventional treatment with cyclophosphamide monthly pulses[9]. In a two-year follow-up, AHSCST was more effective in controlling skin involvement, lung function and improving quality of life than conventional treatment. No deaths were reported. The second study, led by the EBMT, compared 79 transplanted SSc patients with 77 others, treated with cyclophosphamide monthly pulses, showing superiority of AHSCST in terms of overall survival, progression-free survival and quality of life[9]. Although the final outcomes were positive, this study showed a transplant-related mortality of approximately 10%, mainly due to cardiac causes[9]. As result of this and other studies, the EBMT and partners now recommend careful cardiac evaluation before enrolling a patient for AHSCST, aiming to improve patient selection and reduce treatment-related mortality[8]. Cardiac evaluation should include electrocardiogram, echocardiogram, 24h-Holter, cardiac resonance and right-side cardiac catheterization with volume overload[8].

The third study, multicenter randomized, compared 36 SSc patients undergoing myeloablative AHSCST, with 39 treated with cyclophosphamide pulses[10]. The transplant-conditioning regimen included low-dose cyclophosphamide plus total body irradiation and horse ATG. The study demonstrated greater overall survival and progression-free survival in transplanted patients compared to the non-transplanted group. A transplant-related mortality of 3% was observed.

Since 2017, the European League Against Rheumatism (EULAR) has recommended AHSCST for patients with rapidly progressive SSc at risk of organ failure[11]. Since 2018, the ASTCT has also recommended autologous transplantation as standard treatment for severe cases of SSc[12]. Treatment protocols have been refined and incorporated into the routine of several transplant centers.

AHSCST is indicated for patients with diffuse SSc with worsening of skin involvement, or patients with interstitial lung disease with worsening of lung function, in the last 6 months, refractory to immunosuppressive treatment.

**CROHN’S DISEASE**

AHSCST has emerged as a potential treatment for CD due to the chronicity of the disease and lack of therapeutic options in refractory patients. Since 1993, there have been reports of patients with CD who had concomitant leukemias or lymphomas, with complete remission of both diseases after hematopoietic stem cell transplantation. In 2010, researchers from the Northwestern University (Chicago, USA) described the long-term follow-up of 24 patients with severe, active and refractory CD who underwent AHSCST with 200 mg/kg cyclophosphamide and rabbit ATG[13]. The study showed an excellent remission rate after AHSCST, but with high incidence of disease reactivation in the long-term follow-up. The progression-free survival of CD patients was 91% in the first year, 63% in the second, 57% in the third, 39% in the fourth and 19% in the fifth year after AHSCST. Nevertheless, when compared to conventional treatment, AHSCST outcomes are quite encouraging. The Crohn’s Disease Activity Index (CDAI), used in the routine assessment of CD patients, must be less than 150 to indicate remission[14]. Conventional medications (synthetic and biological immunosuppressants) induce clinical remission in 40 to 50% of patients in one year, and this percentage also decreases over time. Thus, when studies show that AHSCST induces clinical remission (CDAI <150) in more than 80% of patients in the first year, these results can be interpreted as favoring AHSCST.

In 2017, the EBMT published a study that included 45 patients with active CD and who were refractory to conventional treatment[15]. Patients were randomized to either only mobilization with 4 g/m2 of cyclophosphamide or to mobilization followed by AHSCST with 200mg/kg of cyclophosphamide plus rabbit ATG. The primary endpoint of this study, however, was excessively stringent, as complete clinical, radiological and endoscopic remission (a sustained dis-
ease remission composite score) should be achieved at the end of the first year. As consequence, there were no differences in the number of patients who met the sustained disease remission target, between transplanted and non-transplanted patients. For secondary endpoints of disease activity, endoscopic activity and use of medical therapy, results favored the group of transplanted patients.

A subsequent reassessment of the results from the same study, using more traditional evaluating tools, led to conclusions that AH SCT promotes clinical and endoscopic benefits, despite the high number of adverse events. Other transplant centers, including from Brazil, have shown beneficial results from non-myeloablative AH SCT. The studies demonstrate acceptable toxicity of the procedure with reduced doses (2 g/m2) of cyclophosphamide in the mobilization phase, and improvement of the immediate and long-term quality of life in patients undergoing AH SCT. The mortality rate was zero in most studies. In a large number of cases, there were endoscopic remissions with healing of lesions and remissions in imaging studies.

Allogeneic HSCT may be a future option. A recent pilot study with 9 patients undergoing allogeneic transplantation showed that the procedure was effective in controlling the disease in the short and long term. However, there was high transplant-related toxicity and one patient died due to infection by adenovirus three months after transplantation.

To date, the EBMT, the Center for International Blood and Marrow Transplant Research (CIBMTR), and communications from the United States and Brazil report a total of 334 transplants for CD, 318 of which are autologous, characterizing this autoimmune disease as the third most frequently transplanted in the world. These data reflect the severity of the disease and the demand for more effective therapeutic resources. Patients with clinically and endoscopically active CD, refractory to conventional treatment including at least two biological drugs, should be indicated for autologous transplantation.

In conclusion, data from national and international studies provide scientific support to recommend AH SCT as treatment for multiple sclerosis, systemic sclerosis and Crohn's disease (Table 1). Allogeneic transplantation, however, should still be further evaluated in the experimental setting.

REFERENCES:


### TABLE 1 – SBTMO recommendations for AHSCT in autoimmune diseases

<table>
<thead>
<tr>
<th>Disease</th>
<th>Autologous transplantation</th>
<th>Allogeneic transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple sclerosis</td>
<td>Recommended/I</td>
<td>Experimental/III</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>Recommended/I</td>
<td>Experimental/III</td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>Recommended/II</td>
<td>Experimental/III</td>
</tr>
</tbody>
</table>

SBTMO: Brazilian Society of Bone and Marrow Transplantation; AHSCT: autologous hematopoietic stem cell transplantation. MSD: matched sibling donor; MUD: matched unrelated donor; MMAD: mismatched alternative donor. Table created by the authors.